Endocrine determinants of obesity

Handbook of Obesity: Etiology and Pathophysiology, Second Edition

Volumn , Issue , 2003, Pages 655-669

  Pinkney, Jonathan H ^a   Kopelman, Peter G ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868203948     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (148)

1. Pinkney JH, Wilding JPH, Williams G, Mac Farlane I. Hypothalamic obesity in humans: What do we know and what can be done? Obesity Reviews 2002; 3:27–34.
2. Lustig RH, Rose SR, Burgben GA, et al. Hypothalamic obesity caused by cranial insult in chldren: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr 1999; 135:162–168.
3. Li Voon Chong JS, Benbow S, Foy P, Wallymahmed ME, Wile D, Mac Farlane IA. Elderly people with hypothalamic-pituitary disease and growth hormone deficiency: lipid profiles, body composition and quality of life compared with control subjects. Clin Endocrinol 2001; 53:551–559.
4. Rosenfalck AM, Mahgsoudi S, Fuisker S, et al. The effect of 30 months of low dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 2000; 85:4173–4181.
5. Chrisoulidou A, Beshyah SA, Rutherford O, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000; 85:3762–3769.
6. Biller BM, Sesmilo G, Baum HB, Hayden D, Shoenfeld D, Klibanski A. Withdrawal of long term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult onset GH deficiency. J Clin Endocrinol Metab 2000; 85:970–976.
7. Stouthart PJ, De Ridder CM, Rekers-Mombarg LT, Van der Wall HA. Changes in body composition during 12 months after discontinuation of growth hormone therapy in young adults with growth hormone deficiency from childhood. J Pediatr Endocrinol Metab 1999; 12:335–338.
8. Farooqi IS, Jebb SA, Langmack G. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341:879–884.
9. Clement K, Vaisse C, lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392:398–401.
10. Krude H, Biebermann H, Luck W, Hom R, Brabant G, Gruters A. Severe early onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19: 155–157.
11. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O' Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited hman obesity. Nat Genet 1998; 20:111–112.
12. Vaisse C, Clement K, Durand E, Hercberg S, Guy- Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000; 106:253–262.
13. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595–1607.
14. De Fronzo RA. The triumvirate: B-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37:667–687.
15. Kolterman OG, Insel J, Sackow M, Olefsky JM. Mechanisms of insulin resistance in human obesity. J Clin Invest 1980; 65:1272–1284.
16. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54:254–260.
17. Peiris AN, Mueller RASGA. Splanchnic insulin metabolism in obesity: influence of body fat distribution. J Clin Invest 1986; 78:1648–1657.
18. Pouliot MC, Despres JP, Nadeau A, Moorjani S, Prud'homme D, Lupien PJ. Visceral obesity in men. Associations of glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41:826–834.
19. Golay A, Swislicki AL, Chen YD, Jaspan JD, Reaven GM. Effect of obesity on ambient plasma glucose, free fatty acid, insulin, growth hormone, and glucagon concentrations. J Clin Endocrinol Metab 1986; 63:481484.
20. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus. Lancet 1963; 785–789.
21. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93:2438–2446.
22. Bjorntorp P. ‘Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10:493–496.
23. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171–176.
24. Evans DJ, Murray R, Kissebah AH. Relationship between skeletal muscle insulin resistance, insulin- mediated glucose disposal and insulin binding effects of obesity and body fat topography. J Clin Invest 1984; 74:1515–1525.
25. Garvey WT, Maianu L, Huecksteadt TP, et al. Pretranslational suppression of a glucose transporter protein causes cellular insulin resistance in noninsulin-dependent diabetes and obesity. J Clin Invest 1991; 87: 1072–1081.
26. Garvey WT, Maianu L, Hancock JA, Golichowski AM, baron A. Gene expression of GLUT4 in skeletal muscle from insulin resistant patients with obesity, IGT, GDM and NIDDM. Diabetes 1992; 41:465475.
27. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001; 409:729–733.
28. Garvey WT, Olefsky JM, Matthaei S, Marshall S. Glucose and insulin coregulate the glucose transport system in primary cultured adipocytes: a new mechanism of insulin resistance. J Biol Chem 1987; 262: 189–197.
29. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes 1998; 22:1145–1158.
30. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actuions of insulin in isolated rat adipocytes. J Bio Chem 1997; 272:10585–10593.
31. Walder K, Filippis A, Clark S, Zimmet P, Collier GR. leptin inhibits insulin binding in isolated rat adipocytes. J Endocrinol 1997; 155:R5–R7.
32. Cases JA, Gabriely I, Ma XH, et al. Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo. Diabetes 2001; 50:348–352.
33. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor—a key component of the obesity-diabetes link. Diabetes 1994; 43:2409–2415.
34. Migeon CJ, Green OC, Eckert JP. Study of adrenocortical function in obesity. Metabolism 1963; 12:718730.
35. Galvao-Tales A, Graves L, Burke CW, et al. Free cortisol in obesity: effect of fasting. Acta Endocrinol 1976; 81: 321–329.
36. Strain GW, Zumoff B, Strain JJ, levin J, Fukushima DK. Cortisol production in obesity. Metabolism 1980; 29:980–985.
37. Ljung T, Andersson B, Bengtsson B-A, Bjorntorp P, Marin P. Inhibition of cortisol secretion by dexame- thasone in relation to body fat distribution: a dose response study. Obes Res 1996; 4:277–282.
38. Marin P, Darin N, Amemiya T, Andersson B, Jern S, Bjorntorp P. Cortisol secretion in relation to body fat distribution in obese premanopausal women. Metabolism 1992; 41:882–886.
39. Slavnov VN, Epstein EV. Somatotrophic, thyrotriphic and adenotrophic functions of the anterior pituitary in obesity. Endocrinologie 1977; 15:213–218.
40. Weaver JU, Kopelman PG, Mc Loughlin L, et al. Hyperactivity of the hypothalamo-pituitary-adrenal axis in obesity: a study of ACTH, AVP, b-lipotropin and cortisol responses to insulin-induced hypoglycaemia. Clin Endocrinol 1993; 39:345–350.
41. Korbonits M, Trainer PJ, Nelson MI, et al. Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. Clin Endocrinol 1996; 45:699–706.
42. Pasquali R, Biscotti M, Spinucci G. Pulsatile rhythm of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution. Clin Endocrinol 1998; 48:603–612.
43. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998; 83: 1853–1859.
44. Cigolini M, Smith U. Human adipose tissue in culture. VIII. Studies on the insulin antagonist effect of glucocorticoids. Metabolism 1979; 28:502–510.
45. Rebuffe-Scrive M, Bronnegard M, Nilsson A. Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab 1990; 71:1215–1219.
46. Bronnegard M, Arner P, Hellstrom L, et al. Gluoco-corticoid receptor messenger ribonucleic acid in different regions of human adipose tissue. Endocrinology 1990; 127:1689–1696.
47. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect Cushing's disease of the omentum? Lancet 1997; 349:1210–1213.
48. Simkin V. 17-Ketosteroid and 17-ketogenic steroid excretion in obese patients. N Engl J Med 1961; 264: 974–977.
49. Kurtz BR, Givens JR, Kominder S, et al. maintenance of normal circulating levels of D-androstenedione and dehydroepiandrosterone in simple obesity despite increased metabolic clearance rates: evidence for a servo-controlled mechanism. J Clin Endocrinol Metab 1987; 64:1261–1267.
50. Williams DP, Boyden TW, Pamenter RW, et al. Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premanopausal females. J Clin Endocrinol Metab 1993; 77:80–85.
51. Usiskin KS, Butterworth S, Clore JN, et al. Lack of effect of dehydroepiandrosterone sulphate in obese men. Int J Obes 1990; 14:457–463.
52. Khaw K-T, Barret-Connor E. Fasting plasma glucose levels and endogenous androgens in non-diabetic postmenopausal women. Clin Sci 1991; 80: 199–203.
53. Brody S, Carlstrom K, Lagrelius K, et al. Adrenal steroid in postmenopausal women: relation to obesity and bone mineral content. Maturitas 1987; 9:25–32.
54. Couch RM, Muller J, Winter JSD. Regulation of the activities of 17-hydroxylase and 17, 20-desmolase in the human adrenal cortex: genetic analysis and inhibition by endogenous steroids. J Clin Endocrinol Metab 1986; 63:613–618.
55. Rebuffe-Scrive M, Krotkiewski M, Elfverson J, Bjorntorp P. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1988; 67:1122–1128.
56. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983; 72:1150–1162.
57. Bouchard C, Bray GA, Hubbard V. Basic and clinical aspects of regional fat distribution. Am J Clin Nutr 1990; 52:946–950.
58. La Fontan M, Dang-Tran L, Berlan M. Alpha-adrenergic antilipolytic effect of adrenaline in human fat cells of the thigh: comparison with adrenal responsiveness of different fat deposits. Eur J Clin Invest 1975; 9:261–266.
59. Rebuffe-Scrive M, Bjorntorp P. Regional adipose tissue metabolism in man. In: Vague J, Bjorntorp P, Guy-Grand B, eds. Metabolic Complications of Human Obesities. Amsterdam: Elsevier North-Holland, 1985:149–159.
60. Wahrenberg H, Lonnqvist F, Arner P. Mechanisms underlying regional differences in lipolysis in human adipose tissue. J Clin Invest 1989; 84:458–467.
61. Rebuffe-Scrive M, Enk L, Crona L, et al. Fat cell metabolism in different regions in women. Effects of menstrual cycle, pregnancy and lactation. J Clin Invest 1985; 75:1973–1976.
62. Kirschner MA, Schneider G, Ertl NH, Worton E. Obesity, androgens, oestrogens and cancer risk. Cancer Res 1982; 42:3281–3285.
63. Evans DJ, Hoffman RG, Kalkhoff R, Kissebah AH. Relationship of androgenic activity of body fat topography, fat cell morphology and metabolic aberrations in postmenpausal women. J Clin Endocrinol Metab 1983; 57:304–310.
64. Samojlik E, Kirschner MA, Silber D, et al. Elevated production and metabolic clearance rates of androgens i morbidly obese women. J Clin Endocrinol Metab 1984; 59:949–954.
65. Vermulen A, Ando S. Metabolic clearance rate and interconversion of androgens and the influence of free androgen fractions. J Clin Endocrinol Metab 1979; 48:320–326.
66. Feher T, Brodrogi L. A comparative study of steroid concentrations in human adipose tissue and peripheral circualation. Clin Chim Acta 1982; 126:135–141.
67. Longcope C, Kato T, Orton R. Conversion of blood androgens to estrogens in normal adult men and women. J Clin Invest 1969; 48:2191–2201.
68. Barbieri RL, Hornstein MD. Hyperinsulinaemia and ovarian hyperandrogenism: cause and effect. Endocrinol Metab Clin North Am 1988; 17:685–703.
69. Sjogren L, Min P. Androgen hormone binding to adipose tissue in rats. Biochim Biophys Acta 1995; 1244:117–120.
70. Marin P, Lonn L, Andersson B, et al. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tisusue in vivo in men. J Clin Invest 1996; 81: 1018–1022.
71. Vettor R, De Pergola G, Pagano C, et al. Gender differences in obese people. Relationship with testosterone, body fat distribution and insulin secretion. Eur J Clin Invest 1997; 27:1016–1024.
72. Aziz R. Reproductive endocrinologic alterations in female asymptomatic obesity. Fertil Steril 1989; 52: 703–725.
73. Zhang Y-W, Stern B, Rebar RW. Endocrine comparison of obese menstruating and amenorrhoeic women. J Clin Endocrinol Metab 1984; 58:1077–1083.
74. Meldrum DR, Davidson BJ, Tatryn IV, Judd HL. Changes in circulating steroids with ageing in postmenopausal women. Obstet Gynecol 1981; 57:404408.
75. Schinder AE, Ebert A, Friedrich E. Conversion of androstenedione to oestrone by human fat tissue. J Clin Endocrinol Metab 1972; 35:627–630.
76. Hemsell DL, Grodin JM, Brenner PF, et al. Plasma precursors of oestrogen. II. Correlation of the extent of conversion of plasma androstenedione to oestrone with age. J Clin Endocrinol Metab 1974; 38:476–479.
77. Longcope C, Baker R, Johnston CCJ. Androgen and estrogen metabolism: relationship to obesity. Metabolism 1986; 35:235–237.
78. Deslypere JP, Verdonek L, Vermulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab 1987; 61:564–570.
79. Roncari DAK, Van RLR. Promotion of human adipocyte precursor replication by 17-b-oestradiol in culture. J Clin Endocrinol Metab 1987; 61:564–570.
80. Anderson DC. Sex hormone binding globulin. J Clin Endocrinol Metab 1974; 3:69–96.
81. Kirschner MA, Samojlik M, Drejka M, et al. Androgen-oestrogen metabolism in women with upper body obesity versus lower body opbesity. J Clin Endocrinol Metab 1990; 70:479.
82. Plymate SR, Matej LA, Jones RA, Friedl KE. Inhibition of sex hormone binding globulin production in human hepatoma (HepG2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988; 67:460–464.
83. Barbieri RR, Makris A, Randall RW, et al. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyper- androgenism. J Clin Endocrinol Metab 1986; 62:904910.
84. Stein IF, Leventhal LM. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181–191.
85. Fisher ER, Gregonon R, Stephen T. Ovarian changes in women with morbid obesity. Obstet Gynecol 1974; 44:839–844.
86. Dunaif A. Polycystic ovary syndrome and obesity. In: Bjorntorp P, Brodoff PN, eds. Obesity. Philadelphia: Lippincott, 1992:594–605.
87. Hausner H, Ditschieneit HM, Pal SB, et al. Fat distribution, endocrine and metabolic profile in obese women with and without hirsutism. Metabolism 1988; 37:281–286.
88. Edman CD, Mac Donald PC. Effect of obesity on conversion of plasma androstendione to oestrone in ovulatory and anovulatory young women. Am J Obstet Gynecol 1978; 130:456–461.
89. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with polycytstic ovary syndrome. J Clin Endocrinol Metab 1991; 72:83–89.
90. Oberfield SE. Metabolic lessons from the study of young adolescents with polycystic overy syndrome—is insulin, indeed, the culprit? J Clin Endocrinol Metab 2001; 85:3520–3525.
91. Franks S, Kiddy D, Sharp P, et al. Obesity and polycystic ovary syndrome. Ann NY Acad Sci 1991; 626:201–206.
92. Geffner ME, Kaplan SA, Bersch N, et al. Persistence of insulin resistance in polycystic ovary disease after inhibition of ovarian steroid secretion. Fertil Steril 1986; 45:327–333.
93. Nestler JE, Barlascini CO, Matt DW, et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with PCOS. J Clin Endocrinol Metab 1989; 68:1027–1032.
94. Velasquez EM, Mendoza S, Hamer, et al. Metformin therapy in polycystic ovary syndrome reduces hyper- insulinemia, hyperandrogenemia and systolic blood pressure while facilitating menses and pregnancy. Metabolism 1994; 43:647–654.
95. Dunaif A, Scott D, Finegood D. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299–3306.
96. Iuonro MJ, Nestler JE. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28:153–164.
97. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617–623.
98. Conway GS, Jacobs HS, Holly JMP, Wass JAH. Effects of luteinizing hormone, insulin-like growth factor small binding protein-1 in the polycystic ovary syndrome. Clin Endocrinol 1990; 33:593–603.
99. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C. The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev 2001; 6: 371–399.
100. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvements in endocrine and ovarian function during dietary treatment of obese women. Clin Endocrinol 1992; 36:105–111.
101. Tanner JM, Whitehouse RH. The effect of human growth hormone on subcutaneous fat thickness in hyposomatrophic and hypopituitary dwarfs. J Endocrinol 1967; 39:263–275.
102. Vahl N, Jorgensen JOL, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol 1997; 272:E1108–E1116.
103. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone deficiency with recombinant human GH. J Clin Endocrinol Metab 1994; 78:960–967.
104. Jorgensen JO, Moller N, Wolthers T, et al. Fuel metabolism in growth hormone-deficient adults. Metabolism 1995; 44:103–107.
105. Maccario M, Grotolli S, Procopio M, et al. The GH/IGF-1 axis in obesity: influence of neuroendocrine and metabolic factors. Int J Obes 2000; 24:S96-S99.
106. Veldhuis J, Liem A, South S, et al. Differential impact of age, sex steroid hormones, and obesity on basal vs pulsatile growth hormone secretion in men as assessed in an ultrasensitivie chemiluminescence assay. J Clin Endocrinol Metab 1995; 80:3209–3222.
107. Langendonk JG, Meinders AE, Burggraaf J. Influence of obesity and body fat distribution on growth hormone kinetics in humans. Am J Physiol 1999; 277:E824–E829.
108. Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991; 72:51–59.
109. Postel-Vinay MC, Saab C, Gourmelen M. Nutritional status and growth hormone binding protein. Horm Res 1995; 44:177–181.
110. Fisker S, Vahl N, Jorgense JO, Christiansen JS, Orskov H. Abdominal fat determines growth hormone-binding protein levels in healthy nonobese adults. J Clin Endocrinol Metab 1997; 82:123–128.
111. Maccarrio M, Arvat E, Procopio M, et al. Metabolic modulation of growth hormone-releasing activity of hexarelin in man. Metabolism 1995; 44:134–138.
112. Alvarez CV, Mallo F, Burguera B, Caciedo L, Dieguez C, Casanueva FF. Evidence for a direct pituitary inhibition by free fatty acids of in vivo growth hormone responses to growth hormone-releasing hormone in the rat. Neuroendocrinology 1991; 53:185189.
113. Maccario M, Procopio M, Grotolli S, et al. In obesity the somatotrope response to either growth hormone- releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose. J Clin Endocrinol Metab 1995; 80:3774–3778.
114. Merimee TJ, Fineberg SE. Dietary regulation of human growth hormone secretion. Metabolism 1973; 22:1491–1497.
115. Yamashita S, Melmed S. Effect of insulin on rat anterior pituitary cells. Diabetes 1986; 35:440–447.
116. Weaver JU, Kopelman PG, Holly JMP, et al. Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor-1 (IGFBP-1) in extreme obesity. Clin Endocrinol 1990; 32:641–646.
117. Bang P, Brismar K, Rosenfeld RG, Hall K. Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding proteins in patients with non-insulin-dependent diabetes versus healthy nonobese and obese subjects. J Clin Endocrinol Metab 1994; 78:960–967.
118. Frystyk J, Skjaerbaek E, Morgensen CE, Orskov H. Free insulin-like growth factor in human obesity. Metabolism 1995; 44:37–44.
119. Maccario M, Tassone F, Gianotti L. Effects of recombinant human insulin-like growth factor 1 administration on the growth hormone (gh) response to GH-releasing hormone in obesity. J Clin Endocrinol Metab 2001; 86:167–171.
120. Johansson G, Marin P, Lonn L. Growth hormone treatment of abdominally obese men reduces abdominal fat mas, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 82:727–734.
121. Richelsen B. Action of growth hormone in adipose tissue. Horm Res 1997; 48:105–110.
122. Karlsson C, Stenlof K, Johansson G. Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men. Eur J Endocrinol 1998; 138:408–414.
123. Bianda TL, Glatz Y, Boeni-Schnetzler M, Froesch ER, Schmid C. Effects of growth hormone (GH) and insulinlike growth factor-1 on serum leptin in GH-deficient adults. Diabetologia 1997; 40:363–364.
124. Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS. Insulin-like growth factor-1 is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem 1988; 263:9402–9408.
125. Rasmussen MH, Hvidberg AJA, Main KM, Gotfred- sen A, Skakkebaek NE, Hilsted J. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-1 levels in obese subjects. J Clin Endocrinol Metab 1995; 80:1407–1415.
126. Rasmussen MH, Ho KK, Kjems L, Hilsted J. Serum growth hormone-binding protein in obesity: effect of short term, very low calorie diet and diet-induced weight loss. J Clin Endocrinol Metab 1996; 81:1519–1524.
127. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656–660.
128. Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 2001; 12:118–122.
129. Dieguez C, Casanueva FF. Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. Eur J Endocrinol 2000; 142:413–417.
130. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathways. Diabetes 2001; 50:227–232.
131. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 2000; 141:4797–4800.
132. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin leveles are decreased in human obesity. Diabetes 2001; 50:707–709.
133. Zhang J, Lazar MA. The mechanism of action of thyroid hormones. Annu Rev Physiol 2000; 62:439–466.
134. Pillar TM, Seitz HJ. Thyroid hormone and gene expression in the regulation of mitochondrial respiratory function. Eur J Endocrinol 1997; 136:231–239.
135. El Hadri K, Pairault J, Feve B. Triiodothyronine regulates beta 3-adrenoceptor expression in 3t3-F442A differentiating adipocytes. Eur J Biochem 1996; 239: 519–525.
136. Rabelo R, Reyes C, Schifman A, Silva JE. Interactions among receptors, thyroid hormone response elements, and ligands in the regulation of the rat uncoupling protein gene expression by thyroid hormone. Endocrinology 1996; 137:3478–3487.
137. Gong D-W, He Y, Karas M, Reitman M. Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone and b3-adrenergic agonists and leptin. J Biol Chem 1997; 272:24129–24132.
138. Arnold S, Goglia F, Kadenbach B. 3, 5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of ATP. Eur J Biochem 1998; 253:325–330.
139. Buscemi S, Verga S, Maneri R, Blunda G, Galluzzo A. Influences of obesity and weight loss on thyroid hormones. A 3–3.5 year follow-up study on obese subjects with surgical biliopancreatic bypass. J Endocrinol Invest 1997; 20:276–281.
140. Stichel H, l' Allemand D, Gruters A. Thyroid function and obesity in children and adolescents. Horm Res 2000; 54:14–19.
141. Scaglione R, Averna MR, Dichiara MA, et al. Thyroid function and release of thyroid-stimulating hormone and prolactin from the pituitary in human obesity. J Int Med Res 1991; 19:389–394.
142. Pinkney JH, Goodrick S, Katz J, et al. Leptin and the pituitary-thyroid axis: comparative study in lean, obese, hyperthyroid and hypothyroid subjects. Clin Endocrinol 1998; 49:583–588.
143. Davidson MB, Chopra IJ. Effect of carbohydrate and non-carbohydrate sources of calories on plasma 3, 5, 3- triiodothyronine concentrations in man. J Clin Endocrinol Metab 1979; 48:577–581.
144. Kvetny J. Nuclear tyroxine receptors and cellular metabolism of thyroxine in obese subjects before and after fasting. Horm Res 1995; 21:60–65.
145. Kinlaw WB, Schwartz HL, Oppenheimer JH. Decreased serum triiodothyronine in starving rats is due primarily to diminished thyroidal secretion of thyroxine. J Clin Invest 1985; 75:1238–1241.
146. Legradi G, Emerson CH, Ahima RS, Flier JS, Lechan RM. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology 1997; 138:2569–2576.
147. Fekete C, Legradi G, Mihaly E. Alpha-melanocyte-stimulating hormone is contained in nerve terminals in thyrotropin-releasing hormone-synthesising neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J Neurosci 2000; 20:1550–1558.
148. Koppeschaar HP, Meinders AE, Shwarz F. Metabolic responses in grossly obese subjects treated with a very-low-calorie diet with and without triiodothyronine treatment. Int J Obes 1983; 7:133–141.